Literature DB >> 30891140

Structure-Activity Relationship Studies of 3- or 4-Pyridine Derivatives of DS-6930.

Tsuyoshi Shinozuka1, Tomoharu Tsukada1, Kunihiko Fujii1, Eri Tokumaru1, Yumi Matsui2, Satoko Wakimoto1, Tsuneaki Ogata1, Kazushi Araki1, Ryoko Sawamura1, Nobuaki Watanabe1, Makoto Mori1, Jun Tanaka1.   

Abstract

Derivatization efforts were continued to discover backups for a potent selective PPARγ modulator, DS-6930. In this Letter, the replacement of 2-pyridine ring in DS-6930 with 3- or 4-pyridyl group is reported. As the introduction of substituents on the pyridine ring did not provide potent partial agonists, modifications of benzimidazole ring were explored to discover potent intermediate agonists. 4'-Alkoxy substituted benzimidazoles failed to show potent efficacy in vivo, whereas 7'-fluoro benzimidazole 3g (DS19161384) was found to result in robust plasma glucose reductions with excellent DMPK profiles.

Entities:  

Year:  2019        PMID: 30891140      PMCID: PMC6421586          DOI: 10.1021/acsmedchemlett.8b00645

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  6 in total

Review 1.  Thiazolidinediones.

Authors:  Hannele Yki-Järvinen
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

2.  Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.

Authors:  Yoon K Loke; Sonal Singh; Curt D Furberg
Journal:  CMAJ       Date:  2008-12-10       Impact factor: 8.262

3.  Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.

Authors:  Jang Hyun Choi; Alexander S Banks; Jennifer L Estall; Shingo Kajimura; Pontus Boström; Dina Laznik; Jorge L Ruas; Michael J Chalmers; Theodore M Kamenecka; Matthias Blüher; Patrick R Griffin; Bruce M Spiegelman
Journal:  Nature       Date:  2010-07-22       Impact factor: 49.962

4.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

Review 5.  Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.

Authors:  Sunder Mudaliar; Anna R Chang; Robert R Henry
Journal:  Endocr Pract       Date:  2003 Sep-Oct       Impact factor: 3.443

6.  Discovery of DS-6930, a potent selective PPARγ modulator. Part II: Lead optimization.

Authors:  Tsuyoshi Shinozuka; Tomoharu Tsukada; Kunihiko Fujii; Eri Tokumaru; Kousei Shimada; Yoshiyuki Onishi; Yumi Matsui; Satoko Wakimoto; Masanori Kuroha; Tsuneaki Ogata; Kazushi Araki; Jun Ohsumi; Ryoko Sawamura; Nobuaki Watanabe; Hideki Yamamoto; Kazunori Fujimoto; Yoshiro Tani; Makoto Mori; Jun Tanaka
Journal:  Bioorg Med Chem       Date:  2018-09-08       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.